Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Share price taken down
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(62)
•••
Comment by WalkOverTheStrton May 15, 2021 3:33pm
249 Views
Post# 33210261

RE:RE:RE:RE:RE:RE:Share price taken down

RE:RE:RE:RE:RE:RE:Share price taken downArbourmark,

My apologies as my word choice was more of frustration of the current stagnation and unclear reason to perform a R/S and then wait half a year or more to list on a major US exchange.   

The the total market capitalization of companies listed on TSX & TSXV is listed from various sources at  $2.3T to $3.2 T, not a figure to dismiss lightly, while the total value than NASDAQ is $12.98T and NYSE is $28.19T but .... I do not assume that Antibe will easily find institutional buyers once on the NASDAQ as part of the limitation on those firms will be the MC of Antibe. Which may also be a limiting factor on the TSX for Canadian institutions. 

There is currently a massive disconnect between potential value in Antibe and the value the market is placing on the company thru MC. Why is this disconnect so massive? I can find countless biotechs on the US that have 1/20th the TAM of Oten but have higher MCs than Antibe. Is it an issue with visibility? With getting more attention from these instrutions? I undertsand Dan is doing virtual road shows with US instituions for a future NASDAQ list so why hasn't he done this on the TSX to Canadian institutions? I honestly do not understand this...


https://www.visualcapitalist.com/the-worlds-10-largest-stock-markets/
https://www.relbanks.com/stock-exchanges/largest-stock-exchanges

https://companiesmarketcap.com/canada/largest-companies-in-canada-by-market-cap/
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities